Vaccines

Benoit Dawant, PhD, left, Erik Tkaczyk, MD, PhD, and colleagues have developed a new way to measure human monkeypox severity.

Vanderbilt study uses AI to speed monkeypox drug trials

A machine learning algorithm developed by researchers at Vanderbilt performs as well as humans at identifying skin lesions in clinical photographs of people with monkeypox.

COVID-19 bivalent vaccine boosters available for employees of VUMC and VU, as well as patients

VUMC study will evaluate alternative strategies for administering monkeypox vaccine

Vanderbilt is seeking about 30 healthy adults of diverse backgrounds to participate in a national clinical trial to evaluate alternative strategies for administering the monkeypox vaccine

Shown here is the research team that discovered monoclonal antibodies that protect against COVID-19 in high-risk individuals.

COVID antibody research conducted at VUMC lands national award

A long-acting antibody combination discovered at Vanderbilt University Medical Center that protects against COVID-19 in high-risk individuals has received a gold medal in the 2022 R&D 100 awards program announced Aug. 22 by R&D World Magazine.

The study team included (front row, from left) Kelsey Voss, PhD, Rachel Bonami, PhD, Erin Wilfong, MD, PhD, (back row, from left) Jonathan Irish, PhD, Jeff Rathmell, PhD, and Ivelin Georgiev, PhD.

Vanderbilt team tracks cellular and antibody responses to COVID-19 vaccine

In a technical tour de force, a collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine.

VUMC research aids approval of COVID-19 vaccine for young children

The U.S. Food and Drug Administration is expected to authorize Pfizer and Moderna’s COVID-19 vaccines for children as young as 6 months old as early as tomorrow, following the unanimous recommendation by an FDA advisory panel on Wednesday.

1 2 3 4 5 15